Executive Team
We are dedicated to improving the lives of those suffering from neurodegenerative diseases. We solve problems with rigorous science and innovative therapies. We have assembled a team with deep scientific, clinical, commercial, and leadership experience and expertise in medical technology and neurodegenerative diseases.
Kent Savage
CEO, Co-Founder
Dan Adams
Science Officer, Co-Founder
Karl Kieburtz, MD, MPH
Medical Officer
Renowned neurologist and former chair of the FDA peripheral and central nervous system advisory Committee and former VP of the American Neurological Association. Iinvolved with every treatment approved by FDA in the last 20 years.
Brett Walker
Marketing Officer
Extensive experience leading product/service launches now producing over a billion dollars annually (Intel, Ancestry, Monster, VitalSmarts, Action Target). Market proficiency across multiple industries and all marketing disciplines.
Samantha John
Commercialization Officer
Formerly with Aimmune Therapeutics, UCB, and Eli Lilly. Brings deep expertise in global commercialization, brand strategy, and patient support across biotech and pharma. Proven success launching complex therapies in specialized markets.
Greg Schneider
Market Access
Formerly with Medtronic, Pfizer, Siemens, Wyath, Extensive drug and device market access expertise with deep experience in Medicare, VA and private coverage, coding, and payments.
Suzanne Hendrix, PhD
Biostatistican
Brad Wyman, PhD
SVP, Science
Mike Drake
VP Quality & Regulatory
Advisory Boards
Clinical & Scientific Advisory Board (CSAB)
Our Clinical & Scientific Advisory Board (CSAB) is comprised of leading experts in Parkinson’s disease (PD) and other neurodegenerative diseases. The board’s aim is to provide clinical and scientific advice and direction to support the PhotoPharmics mission to improve the lives of people who suffer from neurodegenerative diseases. Our leadership in non-invasive specialized light therapy for neurodegenerative diseases benefits from the advice and insight of this world-class advisory board.
Robert A. Hauser, MD, MBA, FAAN, Chair
Ray Chaudhuri, MD
Joohi Jimenez-Shahed, MD
Dan Claassen, MD, MS
Rajesh Pahwa, MD, FAAN
Amy Amara, MD, PhD
George C. Brainard, M.A., Ph.D.
Charles H. Adler, M.D., Ph.D
In Memoriam
Warren Olanow, MD (1941-2024)
Distinguished Physician, Researcher, Colleague, Father, and Friend
The entire PhotoPharmics team mourns the passing of Dr. C. Warren Olanow, a pivotal figure in neurology and chairman of our Clinical and Scientific Advisory Board. Dr. Olanow’s groundbreaking work in Parkinson’s and neurodegenerative research has profoundly advanced our understanding and treatment of movement disorders. His legacy will forever inspire our mission. We extend our heartfelt condolences to his family and honor his lifelong dedication to improving patient lives.
The world is less rich in his absence.
Commercial Advisory Board (CAB)
The Commercial Advisory Board (CAB) brings together accomplished experts in neurology, movement disorders, and the business of bringing new therapies to market. Its role is to advise PhotoPharmics on commercialization strategy, including pricing, access, and adoption, as Celeste® moves toward FDA review and approval. By drawing on this collective experience, PhotoPharmics strengthens its ability to transform specialized light therapy from a clinical breakthrough into an accessible treatment option for people with neurodegenerative diseases.
Jordan Dubow, MD – Chair
Philip Cyr, MPH
Drew Falconer, MD, FAAN
Jill Giordano Farmer, DO, MPH, FCPP, DipABLM
Robert A. Hauser, MD, MBA, FAAN
Rajesh Pahwa, MD, FAAN
Michael Soileau, MD, FAAN
The Cycle of Innovation, Clinical Research, and Improved Lives
For decades, our founders developed innovative specialized phototherapy devices for circadian-related neuropsychiatric disorders. They validated the new devices’ safety and efficacy in human clinical trials and delivered those innovations to and improved the lives of hundreds of
They have now applied their expertise to circadian dysregulation in neurodegenerative disease. Building on this, we have created a new platform technology and developed a safe and convenient product for Parkinson’s patients. PhotoPharmics is now validating this product in robust clinical research. After demonstrating safety and efficacy, these products will become widely available for people with Parkinson’s.
In addition to improving the lives of Parkinson’s patients, recent science and clinical evidence leads us to believe that specialized phototherapy can contribute to the treatment of other neurodegenerative diseases. PhotoPharmics is now applying what we’ve learned in Parkinson’s to other age-related neurodegenerative diseases. We will validate those products in clinical research, and if successful, deliver the solutions to individuals who suffer from these diseases.
WORKING TOGETHER
Join us in improving lives by supporting our innovation and participating in our clinical research.